Table 2.
SCFAs in patients with MS.
| Author | Acetate | Propionate | Butyrate | |||
|---|---|---|---|---|---|---|
| Feces | Blood | Feces | Blood | Feces | Blood | |
| (16) All types MS | No change from healthy controls | No change from healthy controls | Reduction p=0.0045 | Reduction p=0.0006 | No change from healthy controls | No change from healthy controls |
| (15) MS | Reduction | NA | Reduction | NA | Reduction | NA |
| p=0.0001 | p=0.0001 | p=0.05 | ||||
| (18) Patients with SPMS | NA | Reduction | NA | Reduction | NA | Reduction p=0.0001 |
| p=0.001 | p=0.01 | |||||
| (17) Patients with RRMS and SPMS | RRMS: Reduction p<0.001 | NA | RRMS: Reduction p<0.001 | NA | RRMS: Reduction p<0.001 SPMS: | NA |
| SPMS: Reduction in levels but without statistical significance | SPMS: Reduction in levels but without statistical significance | Reduction in levels but without statistical significance | ||||
| (19) Clinically Isolated Syndrome, MS and healthy controls | NA | No difference between MS and healthy control | NA | Reduction reported for CIS/MS group. p=0.0008 | NA | No difference between MS and healthy control |
| (20) RRMS and Clinically Isolated Syndrome | NA | Small but significant reduction in MS | NA | No difference between MS and healthy control | NA | No difference between MS and healthy control |